Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase II NCT07116031

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07116031.

📅 06 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT07116031
Sponsor
Sanofi
Start
2025-12-02
ClinicaliQ Trial Snapshot
  • A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07116031.
  • This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to.
  • Sponsor: Sanofi.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to

Eligibility Snapshot
  • : * Participant must be 1 to 1.5 × ULN (>3 x ULN if Gilbert's syndrome) * Glomerular filtration rate (GFR)

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Guideline
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Respiratory / COPD / Asthma · 25 Mar 2026
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment…
View guideline →
Drug Science
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma
Respiratory / COPD / Asthma · 04 Apr 2026
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma is a clinically relevant Drug Science explainer. Bronchodilation in obstructive airway disease is achieved through…
Explore mechanism →
Guideline
GOLD 2025 Report: Global Strategy for Prevention, Diagnosis and Management of COPD
Respiratory / COPD / Asthma · 31 Mar 2026
GOLD 2025 updates COPD diagnosis criteria: spirometry FEV1/FVC
View guideline →